Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Andernach – page 17

605 clinical trials in Andernach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Andernach at a glance
605
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

605 trials in Andernach

Open in trial search

Hereditary ataxia+1

Recruiting

Study on the Safety of VO659 for Patients with Spinocerebellar Ataxia Types 1, 3, and Huntington's Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:VO659
  • Sponsor:Vico Therapeutics B.V.

Gastric cancer+3

Recruiting

Study of BOLD-100 with FOLFOX chemotherapy (fluorouracil, folinic acid, and oxaliplatin) in patients with advanced gastrointestinal tumors, colorectal, gastric, or pancreatic cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BOLD-100
  • Sponsor:Bold Therapeutics Inc.

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Cisplatin
  • Sponsor:Centre Leon Berard

Study on Chemotherapy with Irinotecan, Fluorouracil, and Oxaliplatin for Patients with Metastatic Colorectal Cancer After Surgery or Ablation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:The University Of Birmingham

Study on Long-term Safety of JNJ-81201887 for Patients with Geographic Atrophy Due to Age-related Macular Degeneration

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Onzemipgene parvec
  • Sponsor:Janssen Cilag International

Study on Venetoclax and Rituximab for Patients with Waldenström’s Macroglobulinemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Universitaetsklinikum Ulm AöR

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Institut Gustave Roussy

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Study on Niraparib, Carboplatin, and Paclitaxel for Advanced Ovarian Cancer Patients After Tumor Removal

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Nord Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V.

Study on the Effectiveness of Volrustomig in Women with High-Risk Locally Advanced Cervical Cancer After Chemoradiation Therapy

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Still's disease

Recruiting

Study of apremilast compared to placebo in children aged 5-17 years with juvenile psoriatic arthritis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Apremilast
  • Sponsor:Amgen Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Andernach

What the registry says about research in the country

01 Analytical, Diagnostic and Therapeutic Techniques and Equipment

Researchers in Andernach are evaluating innovative cell‑based therapies and delivery platforms aimed at repairing knee cartilage damage.

  • Safety profile of UC‑MSC applied on a collagen scaffold
  • Use of Chondro‑Gide® as a supportive matrix
  • Development of minimally invasive implantation methods
  • Implementation of quantitative outcome tools such as KOOS

Both studies are actively recruiting at the sole research site in Andernach, aiming to generate data that could inform future diagnostic and therapeutic standards.

02 Musculoskeletal Diseases

Clinical efforts focus on restoring damaged knee joint cartilage, a prevalent musculoskeletal concern.

  • Evaluation of minced cartilage implantation (AMCI) versus matrix‑associated autologous chondrocyte implantation
  • Management of full‑thickness knee cartilage lesions
  • Assessment of functional recovery through KOOS scores
  • Exploration of long‑term joint health outcomes

The trials seek to improve treatment options for patients with large cartilage injuries and reflect Andernach’s commitment to advancing musculoskeletal research.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.